Tasso Inc., a Seattle, WA-based clinical-grade, at-home, self-sampling blood collection company, closed a $17m Series A financing round.
The round was led by Hambrecht Ducera Growth Ventures and included participation from Foresite Capital, Merck Global Health Innovation Fund, Vertical Venture Partners, Techstars, and Cedars-Sinai. As part of the investment, Elizabeth Hambrecht, Partner at Hambrecht Ducera Growth Ventures, has joined Tasso’s Board of Directors.
The company, which has now raised a total of $38.6m from grants, private investments, and co-development collaborations, will use the proceeds to scale manufacturing and operations.
Led by Ben Casavant, PhD, CEO and Co-founder, Tasso is advancing a line of innovative OnDemand devices, which enable people to collect their own blood using a virtually painless process from anywhere at any time. The samples are then mailed to a CLIA-certified, high-complexity clinical laboratory for analysis. The products are currently being validated for a wide variety of applications, including routine diagnostics, chronic disease monitoring, infectious disease surveillance, athletic and sports testing, virtual clinical trials, global health, and healthcare for under-served populations.
These products are being adopted by academic medical institutions, government agencies, comprehensive cancer centers, and pharmaceutical organizations around the world.